Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has been assigned a $4.00 price target by HC Wainwright in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock.
Separately, Zacks Investment Research downgraded Trillium Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday.
NASDAQ:TRIL traded down $0.03 during mid-day trading on Friday, reaching $0.63. The stock had a trading volume of 1,538,237 shares, compared to its average volume of 844,369. The company has a market capitalization of $13.38 million, a price-to-earnings ratio of -0.27 and a beta of 2.22. Trillium Therapeutics has a 1-year low of $0.51 and a 1-year high of $7.00.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.24. As a group, analysts expect that Trillium Therapeutics will post -1.93 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in Trillium Therapeutics by 164.0% in the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 16,541 shares in the last quarter. Two Sigma Investments LP acquired a new position in Trillium Therapeutics in the fourth quarter worth about $35,000. Jane Street Group LLC acquired a new position in Trillium Therapeutics in the fourth quarter worth about $43,000. Oxford Asset Management LLP grew its stake in Trillium Therapeutics by 64.0% in the first quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 36,534 shares in the last quarter. Finally, Morgan Stanley grew its stake in Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares in the last quarter. Institutional investors and hedge funds own 27.22% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
See Also: What causes a recession?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.